Institute of Good Manufacturing Practices India
Global accredited training & certification provider
Approved by Quality Council Of India (QCI), Government of India
Accredited Vocational Institution of Ministry of HRD, Government of India
An ISO 9001:2008 Certified Organisation
Registered under The Societies Registration Act,1860 Government of India
Empanelled under Ministry of Horticulture and Food Processing, Government of Uttar Pradesh
International Register of Certificated Auditors (IRCA) accredited Lead Auditor (FSMS) course
Affiliated with Life Sciences Sector Skills Council (SSC) and Food Industry Sector Skills Council set up by National Skill Development Corporation (NSDC)
Conferred with QUALITY COUNCIL OF INDIA (QCI) – D.L. SHAH NATIONAL QUALITY AWARD

Trusted by organizations & training participants in over 25 countries
Training | Certification | Education | Research


New Rule for APIs from UK: Need Written Confirmation

As per the Brexit: UK is now established as the ‘Third Country’ and the European Medicines Agency (EMA) and the European Commission intend to provide a series of Brexit related Questions and Answers on the consequences for the pharmaceutical industry. Now, the EMA has published a first set of Q&As. Questions and answers are designed to provide solution to confusion arising due to company’s location and centralised procedures. Certain questions give information about an important aspect of API distribution: the Written Confirmation

As per the Agency "As of the date of the withdrawal of the UK from the Union, active substances manufactured in the UK will be considered imported active substances." This implies APIs imported into the European Union will need to be accompanied by a Written Confirmation from the competent authority of the exporting third country (in this case the UK), pursuant to Article 46b (2) of Directive 2001/83/EC. Following the withdrawal of the UK from the European Union (EU), "medicinal products manufactured in the UK will be considered imported medicinal products". The Agency states that:

The Marketing Authorisation Holder (MAH) must be established in the EU (or EEA states Norway, Iceland and Liechtenstein). This will be also the case for centrally authorised medicinal products. The sponsor of an orphan medicinal product designation must be established in the EU (or EEA).

The Qualified Person for Pharmacovigilance (QPPV) must reside and carry out his/her tasks in a Member State of the EU/EEA. Also the Pharmacovigilance System Master (PSMF) must be located in the EU/EEA.

All production batches imported into the EU/EAA must be analysed/ controlled (again) at a site located in the EU/EEA.

Batch release has to be performed in the EU/EAA. As a consequence, a UK based site for batch release has to transfer this activity "to a location established in the Union (EEA) and submit the corresponding variation".


IGMPI

More

Contact Us